Founded in 2005, AnaptysBio is a privately-held therapeutic antibody company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body’s natural process for generating potent antibodies to fight disease. The Company’s SHM-XEL™ platform couples SHM with other leading-edge technologies to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection – a process that has been referred to as “naturalizing” antibodies. This versatile platform can be used for both discovery of new antibodies and optimization of existing antibodies to generate candidates with desired binding and specificity properties for therapeutic applications.

Our team has extensive technical and business experience in the generation and development of therapeutic antibodies. We have established broad intellectual property around SHM and our SHM-XEL™ platform, and are building a pipeline of novel therapeutic antibodies.
___________________________________________________________________________________________

AnaptysBio's success has the potential to transform the lives of patients from a state of suffering to enjoying life in a way they never thought possible -- again or for the first time. We do this with much stacked in our favor: exceptional talent working on promising technology in a proven field with committed investors. Ultimately, our success depends on our current and future employees – their commitment to the job, ability to solve problems, deal with setbacks and capitalize on opportunities, and our ability to respect each other and work as a team. How we work together as a team and execute our plans will ultimately determine our success. With this in mind, it is our objective to provide you with an environment in which you will excel and cause others to do the same.

A rich experience of learning is what makes AnaptysBio a great place to develop your career.